Sector News

Allergan chops 1,400 jobs to cope with early Restasis generics

January 4, 2018
Life sciences

Back in November, as Allergan was reeling from the news that it could face earlier-than-expected copies of its blockbuster eye drug Restasis, CEO Brent Saunders promised investors that cost cuts were coming “rapidly.”

Just over two months later, they’re here. The company is letting go more than 1,000 staffers across its commercial team and other areas, it said in a Wednesday financial filing. It’s also axing about 400 jobs that aren’t currently filled, for a total job-cutting toll of 1,400. Allergan also plans to squeeze out additional savings through non-headcount related measures—though it didn’t say what those measures were, or how much they would save.

When all is said and done, Allergan expects to shave $300 million to $400 million off the operating cost total it posted for 2017. But that savings will come with an upfront price: The drugmaker expects to rack up a $125 million restructuring bill, primarily paid out in severance to laid-off employees.

Restasis is Allergan’s second-largest product, and it’s now facing down the possibility of generic competition, thanks to a court ruling in mid-October. The job-cut moves come as no surprise considering the assurances Saunders made to worried investors on Allergan’s third-quarter earnings call.

“This team is up for it,” he said at the time, adding, “I hate to say we know how to take costs out of the business, but we do, and we know how to do that in a way that protects the long-term growth drivers.”

The drugmaker has certainly had plenty of practice at job cuts over the last few years. After swallowing Allergan as Actavis, the company slashed 577 jobs at its Irvine, California, headquarters alone as part of a $1.8 billion restructuring.

Some industry watchers, though, would have preferred to see Allergan take a different tack. RBC Capital Markets’ Randall Stanicky, for one, has been lobbying for a company breakup he says could generate $6 billion from a women’s health sale alone.

Meanwhile, the damage is much worse over at Teva, which bought Allergan’s generics business in 2016 for $40.5 billion. Faced with severe pricing pressure in the copycat space, along with a mountain of debt from that deal, the Israeli pharma recently said it would lay off 14,000 workers.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach